Latest News





05-11-15 Zogenix Provides Corporate Update and Reports First Quarter 2015 Financial Results
05-04-15 Zogenix to Release First Quarter 2015 Financial Results and Host Conference Call & Webcast on May 11
04-27-15 Dr. Stephen Farr Appointed as CEO of Zogenix to Lead New Strategic Focus and Advance Late-Stage CNS Product Pipeline

  Relday is a proprietary, once-monthly subcutaneous formulation of risperidone for treating schizophrenia. The Relday Multi-Dose study was initiated in January and results are anticipated in Q3 2015.

  DosePro is a first-in-class, easy-to-use drug delivery system designed for self-administration of a pre-filled, single dose of liquid drug, subcutaneously, without a needle. DosePro offers benefits to patients including instant, easy dosing, less anxiety over self-injection, no need for sharps disposal, no risk of needle stick injury or contamination, and reliable performance.